South Korea confirmed five more cases of Middle East Respiratory Syndrome (MERS), bringing to 30 the number of infected people. Two people have died.» Read More
As a stock market analyst, Janet Yellen makes a pretty good Federal Reserve chair.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
The "Halftime Report" traders give their trades for the second half.
Proposals to deal with a potential Supreme Court ruling could merely delay serious disruption to the insurance market.
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.
Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.
Millions of people could suffer if the Supreme Court strikes down Obamacare subsidies, two doctors tell CNBC.
CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
A campaign accuses the FDA of gender bias for approving drugs to help men have sex, but none for women. The NYT reports.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.
CNBC's Meg Tirrell, and Daniel O'Day, Roche Pharmaceuticals COO, talk about the the encouraging results in treating lung cancer and using precision medicines to personalize treatment.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples, the Pentagon said.
The WHO's analysis of pesticide 2,4-D comes after the group classified another herbicide as "probably" cancer-causing.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Get the best of CNBC in your inbox